Sanofi climbed from 7th to 3rd in the Index, ranking 5th in both commercial and clinical, and 3rd in research. Steadily advancing up the Index since 2022, this rare top five performance across subcategories reflects an organization translating sustained digital investment into consistent value from discovery through to market delivery.

Sanofi continued to advance its vision of “AI from laboratory to bedside. ” In Manufacturing and Supply, the company expanded its Digital Accelerator to scale plant analytics, automation, and modular operations, positioning digital infrastructure as a lever for throughput, reliability, and workforce capability across its sites.

In discovery, Sanofi expanded its partnerships with AQEMIA, leveraging physics-informed generative design, and Enveda, applying AI-guided natural product discovery. Together, these collaborations reflect a pragmatic, long-term strategy that combines advanced modelling with multi-year programs to feed active pipelines.

Clinically, Sanofi focused on AI-assisted recruitment and remote monitoring, unveiling Screening Central, a telehealth entry point for Type 1 diabetes risk. Machine learning models identified Type 1 diabetes risk up to 1- year earlier than traditional diagnostic methods, providing one of the first large-scale demonstrations of predictive AI in endocrinology.

Sanofi also joined Regeneron and Viz.ai to develop an AI- powered Chronic Obstructive Pulmonary Disease (COPD) workflow that uses electronic health records to identify at-risk patients and accelerate coordinated care. The system integrates AI detection into routine practice, supporting both diagnosis and treatment decisions.

In 2025, Sanofi established AI as a core capability rather than a series of pilots, advancing digital transformation across manufacturing, discovery, and clinical care.